

# David H Fitchett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3023797/publications.pdf>

Version: 2024-02-01

98  
papers

19,183  
citations

87888

38  
h-index

39675

94  
g-index

102  
all docs

102  
docs citations

102  
times ranked

14458  
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	27.0	8,841
2	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	27.0	2,809
3	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 752-772.	1.6	932
4	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	8.6	534
5	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
6	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
7	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 90-100.	2.0	333
8	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , 2007, 28, 1072-1078.	2.2	226
9	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019, 139, 1384-1395.	1.6	205
10	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	2.2	199
11	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME®). <i>Cardiovascular Diabetology</i> , 2014, 13, 102.	6.8	198
12	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 317-328.	11.4	195
13	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	1.7	194
14	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	1.7	181
15	Management Patterns in Relation to Risk Stratification Among Patients With Non-ST Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2007, 167, 1009.	3.8	147
16	Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. <i>Canadian Journal of Cardiology</i> , 2011, 27, e1-e33.	1.7	138
17	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. <i>Diabetologia</i> , 2018, 61, 2155-2163.	6.3	133
18	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 405-407.	1.6	131

#	ARTICLE	IF	CITATIONS
19	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018, 138, 1904-1907.	1.6	117
20	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	2.0	112
21	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. <i>American Journal of Cardiology</i> , 2005, 96, 913-916.	1.6	108
22	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 418-435.	11.4	105
23	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 151, 352-359.	2.7	94
24	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017, 19, 43-53.	7.1	91
25	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. <i>Diabetologia</i> , 2018, 61, 1712-1723.	6.3	88
26	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. <i>Age and Ageing</i> , 2019, 48, 859-866.	1.6	79
27	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009, 25, 683-689.	1.7	78
28	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020, 22, 126-135.	7.1	67
29	Optimal Medical Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 530-537.	2.2	64
30	Use of Cardiac Catheterization for Non-ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk & subtitle; Reasons Why Physicians Choose Not to Refer Their Patients & subtitle;. <i>Archives of Internal Medicine</i> , 2008, 168, 291.	3.8	63
31	A safety update on sodium glucose co-transporter 2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 34-42.	4.4	61
32	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 631-639.	4.4	58
33	Statin Intolerance. <i>Circulation</i> , 2015, 131, e389-91.	1.6	53
34	Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. <i>Diabetologia</i> , 2018, 61, 1522-1527.	6.3	49
35	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460.	1.6	49
36	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	3.1	46

#	ARTICLE	IF	CITATIONS
37	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 152, 676-683.	2.7	43
38	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.	11.4	41
39	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005875.	3.9	38
40	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 364-367.	2.8	35
41	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2011, 27, S402-S412.	1.7	33
42	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2006, 151, 373-379.	2.7	32
43	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST-Segment Elevation ACS. <i>Canadian Journal of Cardiology</i> , 2011, 27, S387-S401.	1.7	29
44	Association between uric acid levels and cardiovascular outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1207-1214.	4.4	29
45	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28
46	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2020, 41, 209-217.	2.2	28
47	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	1.7	26
48	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	1.7	25
49	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019, 42, e42-e44.	8.6	25
50	Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy. <i>American Journal of Cardiology</i> , 2008, 102, 1142-1145.	1.6	24
51	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019, 21, 386-388.	7.1	24
52	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , 2020, 33, 1092-1101.	2.0	23
53	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1085-1093.	7.1	23
54	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	3.6	22

#	ARTICLE	IF	CITATIONS
55	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , 2018, 6, 813-822.	4.1	21
56	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1141-1150.	4.4	20
57	Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1042-1047.	1.7	19
58	Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 960-968.	1.7	18
59	Results of the ONTARGET and TRANSCEND studies: an update and discussion. <i>Vascular Health and Risk Management</i> , 2009, 5, 21-9.	2.3	17
60	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 2603-2607.	3.1	16
61	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020, 38, 1829-1840.	0.5	15
62	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020, 7, 3401-3407.	3.1	14
63	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	1.7	14
64	Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. <i>Canadian Journal of Cardiology</i> , 2006, 22, 663-677.	1.7	13
65	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice. <i>European Endocrinology</i> , 2018, 14, 40.	1.5	13
66	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 200.	6.8	13
67	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	4.4	12
68	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , 2018, 34, 736-743.	1.7	10
69	Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i> 2014. 114. 955-961.	1.6	9
70	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	1.7	9
71	SGLT2 inhibitors in the real world: too good to be true?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 673-675.	11.4	9
72	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097525.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Coronary Artery Revascularization in Patients With Diabetes Mellitus. <i>Circulation</i> , 2014, 130, e104-6.	1.6	8
74	The Metabolic Syndrome Is an Important Concept in Therapeutic Decision-Making. <i>Canadian Journal of Cardiology</i> , 2015, 31, 596-600.	1.7	8
75	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	4.4	8
76	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	4.1	8
77	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 1-9.	1.8	7
78	Risk Stratification and Selection for Statin Therapy: Going Beyond Framingham. <i>Canadian Journal of Cardiology</i> , 2014, 30, 667-670.	1.7	7
79	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1221.e11-1221.e18.	1.7	7
80	Management of Acute Coronary Syndromes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S190-S195.	0.8	6
81	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	1.5	6
82	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017, 33, 940-942.	1.7	5
83	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109837.	2.8	5
84	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1350-1361.	1.7	4
85	Clinical trial update: focus on the ONTARGET study. <i>Vascular Health and Risk Management</i> , 2007, 3, 901-8.	2.3	4
86	Potential role of rivaroxaban in patients with acute coronary syndrome. <i>Drug Design, Development and Therapy</i> , 2012, 6, 349.	4.3	3
87	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , 2015, 115, 1005-1012.	1.6	3
88	Impaired Cardiac Function in Metabolic Syndrome. <i>Canadian Journal of Cardiology</i> , 2014, 30, 270-271.	1.7	2
89	Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies. <i>Canadian Journal of Diabetes</i> , 2015, 39, S176-S182.	0.8	2
90	Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1362-1364.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Acute Coronary Syndromes: A Canadian Perspective. Canadian Journal of Cardiology, 2011, 27, S385-S386.	1.7	1
92	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes, 2020, 69, 131-LB.	0.6	1
93	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. Canadian Journal of Cardiology, 2005, 21, 501-7.	1.7	1
94	Tailored antithrombotic therapy for acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2008, 6, 935-944.	1.5	0
95	Optimizing the Prevention of Cardiovascular Events. Canadian Journal of Cardiology, 2016, 32, S13-S14.	1.7	0
96	Editorial commentary: Anti-glycemic drugs and heart failureâ€”A new era. Trends in Cardiovascular Medicine, 2017, 27, 152-154.	4.9	0
97	To Risk Stratify or Not for Statin Therapy. Canadian Journal of Cardiology, 2019, 35, 550-551.	1.7	0
98	Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0